Purpose
To determine the safety and efficacy of adding topical bromfenac 0.09% in the treatment of diabetic macular edema.
Methods
Seventy patients (70 eyes) with centre involved diabetic macular edema (DME) with macular thickness (300-500um) were included. Patients were divided randomly into two groups; 35 eyes in each group. Both groups were treated with intravitreal ranibizumab monthly for three consecutive months. Bromfenac 0.09% eye drops twice daily was added to treatment of study group for six months from commencement of treatment. Efficacy of topical bromfenac was evaluated by comparing both groups through follow-up period as regards to visual acuity, central retinal thickness and the need of re-injection.
Results
Patients treated with topical bromfenac in addition to intravitreal ranibizumab revealed significant improvement in visual acuity, more reduction in central and average macular thickness; and less tendency to need reinjection compared to those treated with ranibizumab alone (p 0.013, p 0.010 and p 0.022 respectively).
Conclusion
Topical bromfenac 0.09 % twice a day could enhance and sustain the efficacy of intravitreal ranibizumab in the treatment of diabetic macular edema without increase incidence of corneal side effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.